Company intelligence / Profile preview

Verve Market

Cambridge, Massachusetts, United Statesvervemarket.com ↗

Ownership: Private
Employees: ~125
Development stage: Commercial

Overview

Verve’s lead program, VERVE‑102, demonstrated positive initial data in a Phase 1b trial showing safety and promising LDL cholesterol reduction in patients with HeFH or premature CAD. The company plans to initiate a Phase 2 trial in late 2025. Additional programs targeting ANGPTL3 and LPA are advancing through preclinical or early clinical development. The approach aims to provide one-time gene-editing treatments that permanently lower cardiovascular risk factors.

Therapeutic areas: Cardiovascular
Modalities: Gene therapyCRISPR-based therapyBase editing therapyLipid nanoparticle delivery therapy
Industry: Biotech

Partnerships

Eli Lilly and Company

Beyond the preview

Go deeper on Verve Market.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Verve Market.

Explore the full profile